SciBase
SciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, serving dermatology clinics and healthcare providers in the US and European markets through direct enterprise sales and a recurring electrode consumable model.
- Company typePublic
- Founded1998
- HeadquartersStockholm, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What SciBase does
SciBase Holding AB is a Swedish medical technology company founded in 1998 and listed on Nasdaq First North Growth Market under the ticker sto:SCIB. The company develops and commercializes Nevisense, an FDA-approved and CE-marked diagnostic device based on Electrical Impedance Spectroscopy (EIS) technology that provides objective diagnostic data for melanoma and non-melanoma skin cancer detection. The platform analyzes electrical impedance measurements from skin tissue to support clinical decisions in dermatology, with the technology included in US NCCN Clinical Practice Guidelines for Melanoma and over 400,000 tests sold globally. SciBase is expanding the platform's clinical applications into atopic dermatitis prediction in newborns, age-related skin barrier assessment, and detection of chemical-induced skin barrier damage, supported by a portfolio of research collaborations with institutions including Mount Sinai, UCSF, and the Swiss Institute of Allergy and Asthma Research.
The company operates a hybrid hardware-and-consumables revenue model: Nevisense devices are sold to dermatology clinics and healthcare systems in the US and European markets, while single-use electrodes generate recurring revenue, with Q1 2026 electrode sales volume of 30,460 units (up 70% YoY). SciBase has an expanded collaboration and license agreement with Castle Biosciences that includes a SEK 20 million loan convertible to equity, and the company is pursuing US market expansion funded by a SEK 83 million rights issue completed in early 2026. Distribution is primarily through direct enterprise field sales targeting dermatologists and healthcare providers, with expanded labeling now allowing physician assistants and medical assistants to perform the procedure. FY 2025 net sales totaled TSEK 40,461 (up 36% YoY), with Q1 2026 revenue of TSEK 14,278 (up 61% YoY), while the company reported a FY 2025 loss of TSEK 87,063 reflecting continued investment in commercialization and clinical development.
SciBase firmographics
Firmographics- Name
- SciBase
- Legal name
- SciBase Holding AB
- Website
- https://scibase.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- SciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, serving dermatology clinics and healthcare providers in the US and European markets through direct enterprise sales and a recurring electrode consumable model.
- Ownership category
- akta.pro rank
SciBase industry classification
Industry- Product category
- Dermatology Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industry
- Dermatopathology (HLAKACAC)
Keywords
Where SciBase is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
SciBase business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Nevisense Device Sales: Sale of the Nevisense hardware device to dermatology clinics and healthcare systems for melanoma detection and skin barrier assessment.
- Electrode/Test Consumables: Recurring sales of electrodes for the Nevisense device. Q1 2026 saw 70% increase in electrode sales volume reaching 30,460 units.
- Licensing and Collaboration Revenue: Expanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders, including loan agreement of SEK 20 million with potential conversion to equity.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
SciBase product offering
Product offeringCore offering
SciBase develops, manufactures, and commercializes the Nevisense medical diagnostic device, an FDA-approved and CE-marked platform based on Electrical Impedance Spectroscopy (EIS) for melanoma and non-melanoma skin cancer detection. The company sells the Nevisense hardware together with single-use electrodes as recurring consumables to dermatology clinics and healthcare providers, and has expanded applications to atopic dermatitis prediction and skin barrier assessment.
Product overview
SciBase offers the Nevisense platform, a medical diagnostic system based on Electrical Impedance Spectroscopy (EIS) technology. The core Nevisense device is an FDA-approved and CE-marked in-vitro diagnostic tool primarily used for melanoma and non-melanoma skin cancer detection, with expanding applications in atopic dermatitis prediction and assessment. The company sells the device along with single-use electrodes as consumables. The EIS technology provides objective, quantitative measurements that complement visual assessment and dermoscopy, enabling clinicians to make more informed early detection decisions.
Differentiator
Problem solved
Functional benefit
Brands
- Nevisense: Electrical Impedance Spectroscopy (EIS) diagnostic device for melanoma detection and skin barrier assessment
Products and services
- Nevisense Device
Quantifiable outcome
- Melanoma detection accuracy improved with statistically significant and clinically meaningful results over visual assessment and dermoscopy alone
- +4 more outcomes
Companies that use SciBase
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
SciBase technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
SciBase partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and minor.
- Castle Biosciences (DETECT-AD Study)coreDETECT-AD clinical study - multicenter prospective trial to assess ability of SciBase's EIS technology to predict flares in atopic dermatitis. Aims to shift treatment from reactive to proactive care.
- Icahn School of Medicine at Mount SinaicoreResearch collaboration demonstrating that Nevisense measurements taken within first days of life can identify infants who later develop atopic dermatitis during their first year. Study published in journal Allergy.
- Swiss Institute of Allergy and Asthma Research (SIAF)majorEx-vivo study demonstrating Nevisense can detect skin barrier disruption caused by surfactants in household cleaning products. Results published in Allergy journal.
- UCSF (University of California, San Francisco)majorResearch collaboration at Society for Investigative Dermatology Annual Meeting demonstrating Nevisense's ability to detect and quantify age-related changes in skin barrier. Cross-sectional study compared EIS measurements between young and older adults.
- Castle BiosciencescoreExpanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders. Includes SEK 20 million loan agreement with potential conversion to equity to support production ramp-up and growth. Collaboration initiated June 2025 and expanded November 2025.
- Vator SecuritiesminorAdvisory support for directed share issue transaction.
- Advokatfirman SchjødtminorLegal advisory support for directed share issue transaction.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
SciBase competitors and assessment
Company assessmentDirect peers
- Castle Biosciences: Castle Biosciences develops molecular diagnostic tests for dermatologic conditions including DecisionDx-Melanoma and is SciBase's collaboration partner on the DETECT-AD atopic dermatitis program. Directly comparable as both target the dermatology diagnostic decision point, though Castle operates in genomics rather than impedance spectroscopy.
- DermTech: DermTech offers the Pigmented Lesion Assay, a non-invasive adhesive patch genomic test for melanoma. Directly competes with Nevisense at the melanoma detection decision point, targeting the same dermatology clinicians with an alternative non-visual diagnostic technology.
- FotoFinder Systems: FotoFinder manufactures dermoscopy and total body photography systems used in dermatology clinics for melanoma screening. Targets the same dermatologists as Nevisense but with imaging-based rather than impedance-based diagnostics.
- Canfield Scientific: Canfield Scientific provides VECTRA whole-body imaging and DermaGraphix software for dermatology practices. Sells complementary melanoma-screening technology to the same dermatology clinic channel as Nevisense.
- DermLite: DermLite designs and manufactures handheld dermatoscopes widely used by dermatologists for melanoma screening. Represents the incumbent visual/dermoscopy standard against which Nevisense claims statistically significant improvement.
- Heine Optotechnik: Heine is a leading manufacturer of dermatoscopes and dermatological diagnostic instruments. Competes with Nevisense in dermatology clinics as a long-established provider of skin cancer diagnostic hardware.
Emerging players
- SkinVision: SkinVision provides an AI-driven smartphone application for skin cancer risk assessment. Competes with Nevisense at the early melanoma triage stage using a lower-friction, lower-cost consumer-grade modality rather than a clinical device.
- Michelson Diagnostics: Michelson Diagnostics develops VivaScope confocal microscopy for non-invasive skin imaging. Addresses the same dermatology diagnostic workflow as Nevisense with optical rather than electrical measurement technology.
- Skin Analytics: Skin Analytics offers an AI-based dermatology decision support tool (DERM) approved in the UK for skin cancer triage. Emerging alternative to Nevisense leveraging AI image analysis rather than impedance spectroscopy.
Broad incumbents
- Strata Skin Sciences: Strata Skin Sciences markets dermatology diagnostic and therapeutic devices including the VTRAC excimer lamp. Broader dermatology device incumbent with overlapping physician customer base but focused on treatment rather than melanoma detection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SciBase social profiles
Digital presenceSciBase compliance and trust
Trust signalCompliance2 records
SciBase financial estimates
Financial estimateRevenue estimate
Valuation estimate
SciBase leadership team
Management profileNumber of profiles
Profiles5 records
SciBase funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SciBase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SciBase
What does SciBase do?
SciBase develops, manufactures, and commercializes the Nevisense medical diagnostic device, an FDA-approved and CE-marked platform based on Electrical Impedance Spectroscopy (EIS) for melanoma and non-melanoma skin cancer detection. The company sells the Nevisense hardware together with single-use electrodes as recurring consumables to dermatology clinics and healthcare providers, and has expanded applications to atopic dermatitis prediction and skin barrier assessment.
Is SciBase a public or private company?
SciBase is a public company. It is classified as public and is currently operating.
When was SciBase founded?
SciBase was founded in 1998. It employs 51 to 100 people.
Where is SciBase based?
SciBase is headquartered in Stockholm, Sweden, in the Europe region.
How does SciBase make money?
Three revenue lines are on record. Nevisense Device Sales are the primary driver. The others are electrode/Test Consumables and licensing and Collaboration Revenue.
Who are SciBase's main competitors?
Direct peers on record are Castle Biosciences, DermTech, FotoFinder Systems, Canfield Scientific, DermLite and Heine Optotechnik. Emerging players are SkinVision, Michelson Diagnostics and Skin Analytics. Strata Skin Sciences is listed as a broad incumbent.
Does SciBase have an API?
No public API is recorded for SciBase.
What industry is SciBase in?
SciBase's product category is Dermatology Medical Devices. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAKACAC, Dermatopathology. Its NAICS code is 334510 and its SIC code is 3845.